Antigens that may trigger diabetes identified

Image
Press Trust of India Washington
Last Updated : Feb 15 2016 | 1:32 PM IST
Scientists have identified a new class of antigens that may be a contributing factor to type 1 diabetes.
Type 1 diabetes is the autoimmune form of diabetes, in which insulin-producing beta cells in the pancreas are destroyed by immune cells, especially those known as T cells.
In autoimmune disease, the key question is why the immune system attacks the body's own tissues.
Insulin is the hormone that regulates levels of glucose in the blood and without insulin, a life-threatening disease results. Currently, there is no cure for type 1 diabetes.
"Our lab studies the type of T cell known as a CD4 T cell. We have focused on autoreactive CD4 T cells using a mouse model of autoimmune diabetes," said Kathryn Haskins from University of Colorado in US.
"We have been especially interested in identifying the antigens that activate these T cells," said Haskins.
Antigens for T cells are pieces of proteins, or protein fragments (peptides) that have to be taken up and presented to the T cells by antigen-presenting cells. Normally, a CD4 T cell is supposed to respond to 'foreign' antigens, like a viral peptide.
But in autoimmune disease, the autoreactive CD4 T cells respond to peptides that are generated in the body. Such peptides are called autoantigens.
When an autoreactive T cell sees its antigen, it becomes activated and can initiate disease. By identifying those antigens, scientists may be able to use that information to detect autoreactive T cells early in disease, or better yet, in at-risk individuals.
If they are able to use the antigens to turn off destructive T cells, they may be able to prevent the disease.
Researchers conducted experiments to analyse the fractions of beta cells that contain antigen for autoreactive CD4 T cells in order to identify autoantigens in type 1 diabetes.
They discovered a new class of antigens that consist of insulin fragments fused to peptides of other proteins present in beta cells. That fusion leads to generation of hybrid insulin peptides that are not encoded in an individual's genome.
If peptides in the body are modified from their original form, they essentially become 'foreign' to the immune system and this may explain why they become targets for the autoreactive T cells, researchers said.
The discovery of hybrid peptides as targets of the immune system provides a plausible explanation of how the immune system is tricked into destroying the body's own beta cells.
The discovery may also lead to a better understanding of other autoimmune diseases.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Feb 15 2016 | 1:32 PM IST

Next Story